by Blood plasma derivatives find extensive application in various therapeutic areas such as immunology, hematology, critical care medicine, and others. These derivatives include albumin, factor VIII, factor IX, immunoglobulin, hyperimmunoglobin, and others which play a vital role in the treatment of various chronic diseases such as hemophilia, idiopathic thrombocytopenic purpura, primary immune deficiency diseases and other bleeding and immunological disorders.
The global Blood Plasma Derivatives Market is estimated to be valued at US$ 44.33 Bn in 2023 and is expected to exhibit a CAGR of 13% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The key trend in the Global Blood Plasma Derivatives Market Size is the increasing focus on further fractionation of plasma proteins and development of recombinant versions of plasma derived proteins. Manufacturers are focusing on developing advanced plasma fractionation technologies to obtain highly purified plasma derived products with increased yields. For instance, CSL Behring developed patented plasmapheresis technology Caplucizumab which helps in isolating specific immunoglobulin. Also, ongoing research in gene therapy and recombinant protein technology has led to the development of recombinant versions of factor VIII and IX for hemophilia treatment. This is expected to reduce the dependency on plasma-derived versions over the forecast period.
Porter’s Analysis
Threat of new entrants: The blood plasma derivatives market requires high R&D investments and regulatory approvals which pose significant barriers for new companies.
Bargaining power of buyers: Individual buyers have low bargaining power due to availability of a wide range of plasma derivative products from different manufacturers.
Bargaining power of suppliers: Plasma collection organizations are the major suppliers in this market. Increase in plasma collection centers enhances suppliers bargaining power.
Threat of new substitutes: Currently there are no effective substitutes for plasma derivatives limiting threat from substitutes.
Competitive rivalry: The market is dominated by large multinational players intensifying competitive rivalry.
Key Takeaways
The global Blood Plasma Derivatives market is expected to witness high growth. The market size for 2023 is estimated to be US$ 44.33 Bn registering a CAGR of 13% during the forecast period.
Regional analysis: North America dominates the market currently owing to high investments in research and availability of advanced healthcare facilities. Asia Pacific is expected to witness fastest growth over the forecast period supported by increasing healthcare investments and expanding plasma collection infrastructure in major countries like China and India.
Key players: Key players operating in the Blood Plasma Derivatives market are Thermo Fisher Scientific, Inc., Custom Biogenic Systems, Chart Biomedical Co. Ltd., Merck KGaA, Barber-Nichols Inc., Praxair Technology, Inc., Linde LLC, Planer PLC, Cryologic Pty. Ltd., Charter Medicals, Nikkiso Cryo Inc., Cryogenic Control, and Haimen United Laboratory Equipment Development Co., Ltd. Thermo Fisher Scientific and Merck KGaA are the market leaders with strong global presence and wide product portfolio.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
